Division of Infectious Diseases, Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno" (CEMIC) , Buenos Aires, Argentina.
Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno" (CEMIC) , Buenos Aires, Argentina.
Expert Rev Clin Pharmacol. 2020 Jun;13(6):577-592. doi: 10.1080/17512433.2020.1774362. Epub 2020 Jun 16.
Acute bacterial skin and skin structure infections (ABSSSI) are among the most frequent infectious diseases. Recently, several new antibiotics with activity against MRSA have been approved. Tedizolid, a second-generation oxazolidinone approved for ABSSSI offers theoretical advantages over first-generation oxazolidinones.
A comprehensive online search of Medline, ClinicalTrials.gov, and conference presentations was made, selecting articles between January 2000 and April 2020. In this review, the authors discuss the chemical and microbiological properties of tedizolid, summarize its efficacy, safety, and potential role in the treatment of ABSSSI as well as the potential for future indications.
Tedizolid has proven to be non-inferior compared to linezolid for the treatment of ABSSSI in two registrational phase III clinical trials, being well tolerated. Tedizolid exhibits antibacterial activity against the most important ABSSSI pathogens (including multidrug-resistant strains of MRSA), as well as mycobacteria and Nocardia. It appears to have a safe profile, including decreased myelotoxicity and no significant drug interactions. Preliminary studies with longer duration of therapy seem to confirm these potential benefits. Overall, tedizolid expands the newly acquired armamentarium to treat ABSSSI. The role of tedizolid for other indications is under investigation and has yet to be determined.
急性细菌性皮肤和皮肤结构感染（ABSSSI）是最常见的传染病之一。最近，批准了几种对 MRSA 有活性的新型抗生素。替加环素是一种第二代恶唑烷酮类抗生素，被批准用于 ABSSSI，与第一代恶唑烷酮类抗生素相比具有理论优势。
对 Medline、ClinicalTrials.gov 和会议报告进行了全面的在线搜索，选择了 2000 年 1 月至 2020 年 4 月期间的文章。在这篇综述中，作者讨论了替加环素的化学和微生物学特性，总结了其疗效、安全性以及在 ABSSSI 治疗中的潜在作用，以及未来适应症的潜力。
替加环素在两项注册 III 期临床试验中被证明与利奈唑胺相比非劣效，具有良好的耐受性。替加环素对 ABSSSI 最重要的病原体（包括耐多药的 MRSA 株）以及分枝杆菌和诺卡氏菌具有抗菌活性。它似乎具有安全的特性，包括骨髓抑制毒性降低和无明显的药物相互作用。初步研究表明，更长时间的治疗似乎证实了这些潜在的益处。总的来说，替加环素扩大了新获得的治疗 ABSSSI 的武器库。替加环素用于其他适应症的作用正在研究中，尚未确定。
